EP1051169A4 - Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees - Google Patents

Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees

Info

Publication number
EP1051169A4
EP1051169A4 EP99905546A EP99905546A EP1051169A4 EP 1051169 A4 EP1051169 A4 EP 1051169A4 EP 99905546 A EP99905546 A EP 99905546A EP 99905546 A EP99905546 A EP 99905546A EP 1051169 A4 EP1051169 A4 EP 1051169A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treating
compounds
methods
associated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99905546A
Other languages
German (de)
English (en)
Other versions
EP1051169A1 (fr
Inventor
Theodore J Nitz
Daniel C Pevear
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viropharma Biologics LLC
Original Assignee
Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viropharma Inc filed Critical Viropharma Inc
Publication of EP1051169A1 publication Critical patent/EP1051169A1/fr
Publication of EP1051169A4 publication Critical patent/EP1051169A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP99905546A 1998-01-29 1999-01-29 Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees Withdrawn EP1051169A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7303898P 1998-01-29 1998-01-29
US73038P 1998-01-29
US7307898P 1998-01-30 1998-01-30
US73078P 1998-01-30
PCT/US1999/001985 WO1999038508A1 (fr) 1998-01-29 1999-01-29 Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees

Publications (2)

Publication Number Publication Date
EP1051169A1 EP1051169A1 (fr) 2000-11-15
EP1051169A4 true EP1051169A4 (fr) 2002-05-29

Family

ID=26754055

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99905546A Withdrawn EP1051169A4 (fr) 1998-01-29 1999-01-29 Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees

Country Status (9)

Country Link
EP (1) EP1051169A4 (fr)
JP (1) JP2002501894A (fr)
CN (1) CN1289248A (fr)
AU (1) AU759772B2 (fr)
BR (1) BR9908522A (fr)
CA (1) CA2319465C (fr)
MX (1) MXPA00007394A (fr)
NZ (1) NZ505894A (fr)
WO (1) WO1999038508A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489338B2 (en) 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
CA2495266A1 (fr) * 2002-08-09 2004-02-19 Viropharma Incorporated Composes, compositions et techniques de traitement et de prevention de l'infection par des pneumovirus et de maladies associees
AU2003258177A1 (en) 2002-08-09 2004-02-25 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP1682547B1 (fr) 2003-10-30 2012-10-24 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs polymerase rsv
KR101164258B1 (ko) 2003-12-23 2012-07-11 아스텍스 테라퓨틱스 리미티드 단백질 키나아제 조절제로서의 피라졸 유도체
WO2006136821A1 (fr) 2005-06-22 2006-12-28 Astex Therapeutics Limited Composes pharmaceutiques
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
IN2014DN10680A (fr) * 2012-06-29 2015-08-28 Microdose Therapeutx Inc
US9850251B2 (en) 2013-12-10 2017-12-26 Shandong Danhong Pharmaceutical Co., Ltd. Imidazole derivative used as antiviral agent and use therof in preparation of medicament
EP3305790B1 (fr) 2015-06-08 2020-08-05 Shangdong Danhong Pharmaceutical Co., Ltd. Procédé de préparation d'un dérivé d'imidazole et d'un intermédiaire de celui-ci et sa forme cristalline
CN114390929A (zh) * 2019-06-13 2022-04-22 奇达拉治疗公司 用于治疗呼吸道合胞病毒的组合物及方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508391A (en) * 1975-01-20 1978-04-26 Sterling Drug Inc Phenylalkylamines
US4324794A (en) * 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
US5098920A (en) * 1990-05-04 1992-03-24 G. D. Searle & Co. 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
WO1995000131A1 (fr) * 1993-06-23 1995-01-05 Cambridge Neuroscience, Incorporated Ligands du recepteur sigma et leur utilisation
EP0795549A1 (fr) * 1996-02-13 1997-09-17 American Cyanamid Company Dérivés de bis-aryloxy(amino)-triazinyl-oxy(amino)aryl, leur préparation et leur utilisation comme agents antiviraux

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005125A1 (fr) * 1995-07-27 1997-02-13 Warner-Lambert Company Phenols a substitution utilises comme nouveaux antagonistes des canaux calciques lents
JP2000506538A (ja) * 1996-03-29 2000-05-30 ジー．ディー．サール アンド カンパニー メタ―置換フェニレン誘導体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508391A (en) * 1975-01-20 1978-04-26 Sterling Drug Inc Phenylalkylamines
US4324794A (en) * 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
US5098920A (en) * 1990-05-04 1992-03-24 G. D. Searle & Co. 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
WO1995000131A1 (fr) * 1993-06-23 1995-01-05 Cambridge Neuroscience, Incorporated Ligands du recepteur sigma et leur utilisation
EP0795549A1 (fr) * 1996-02-13 1997-09-17 American Cyanamid Company Dérivés de bis-aryloxy(amino)-triazinyl-oxy(amino)aryl, leur préparation et leur utilisation comme agents antiviraux

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAKER, B.R. ET AL: "Irreversible Enzyme Inhibitors. 181. Inhibition of Brain Choline Acetyltransferase by Derivatives of 4-Stilbazole", J. MED. CHEM., 1984, pages 315 - 322, XP000938518 *
DE CLERCQ, ERIK: "Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 7, 1996, pages 193 - 202, XP002193685 *
SCHLEGEL, DONALD C. ET AL: "Bulky amine analogs of ketoprofen: potent antiinflammatory agents", J. MED. CHEM. (1984), 27(12), 1682-90, XP000973055 *
See also references of WO9938508A1 *

Also Published As

Publication number Publication date
AU759772B2 (en) 2003-05-01
JP2002501894A (ja) 2002-01-22
MXPA00007394A (es) 2003-08-01
CA2319465A1 (fr) 1999-08-05
CA2319465C (fr) 2013-03-19
NZ505894A (en) 2002-12-20
CN1289248A (zh) 2001-03-28
EP1051169A1 (fr) 2000-11-15
BR9908522A (pt) 2001-10-02
WO1999038508A1 (fr) 1999-08-05

Similar Documents

Publication Publication Date Title
EP1128832A4 (fr) Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees
EP1109580A4 (fr) Methodes de traitement ou de prevention des infections virales et des maladies associees
EP1115286A4 (fr) Procedes de traitement ou de prevention d'infections virales et de maladies associees
HUP0100765A3 (en) Composition for the treatment of halitosis
IL142906A0 (en) Methods and compositions for treating or preventing peripheral neuropathies
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
HK1048987A1 (zh) 化合物，合成劑及剌激神經元生長及延長的方法
ZA200007642B (en) Treatment of airborne microorganisms.
ZA200108215B (en) Compositions and methods for treatment of staphylococcal infection.
EP1109548A4 (fr) Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses
EP1051169A4 (fr) Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees
AU4314199A (en) Compounds, compositions and methods for treating erectile dysfunction
HK1041827A1 (en) Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the dame.
EP0920419A4 (fr) Composes, compositions et procedes de traitement de la grippe
ZA200203435B (en) Method and compositions for treating pulmonary diseases.
IL133760A0 (en) Composition for the treatment of dandruff
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
HUP0102772A3 (en) Novel compounds derived from alpha-d-xylose, preparation method and therapeutic use
EP1096927A4 (fr) Composition pour le traitement du stress
AU6798000A (en) Compounds, compositions and methods for treating influenza
AU2003258177A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
PL345598A1 (en) Compounds, compositions, and methods for stimulating neuronal growth and elongation
ZA200007396B (en) Method of treatment.
HUP9900123A3 (en) 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000807

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 257/06 A, 7A 61K 31/41 B, 7C 07D 249/14 B, 7C 07D 257/04 B, 7C 07D 277/24 B, 7C 07D 261/08 B, 7C 07D 401/10 B, 7C 07D 233/54 B, 7A 61K 31/415 B, 7A 61K 31/42 B, 7A 61K 31/425 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020412

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040817

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1029938

Country of ref document: HK